Alnylam Pharmaceuticals Inc. Common Stock (ALNY)

FairStock Score: 55/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Alnylam as a Graham-style skeptic and a Buffett-style business analyst. This is a commercial-stage RNAi company with approved medicines such as ONPATTRO, AMVUTTRA, Leqvio, Qfitlia, GIVLAARI and OXLUMO. The turnaround is real: in fiscal 2025, the year ended 2025-12-31, revenue was $3.7 billion and net income was $313.7 million, compared with a $278.2 million net loss in fiscal 2024, the year ended 2024-12-31. In the quarter ended 2026-06-30, revenue was $1.3 billion, net income $164.5 million, and diluted EPS $1.21. Trailing free cash flow was $819.9 million, a 2.7% FCF yield on the $29.9 billion market cap. Those are signs of a genuine platform, not just a story. Yet the price leaves little room for error. At the 2026-10-13 close of $223.82, FairStock calculates a P/E of 38.93, P/B of 22.09, Graham Number of $36.20, and a negative margin of safety of 518.29%. The balance sheet carries a debt-to-equity ratio of 2.21, with ROCE at 12.34%. Piotroski F-Score is 5/9 and FairStock Score 48/100. The Lynch category is TURNAROUND — returned to profit after a loss within the last three years — which fits, but biotech turnarounds can be uneven. PEG of 0.12 looks attractive only if growth persists. I would want durable revenue from the approved portfolio, improving margins, and lower leverage before calling this a Graham bargain. Quality is emerging; the valuation is not defensive.

In plain English: Alnylam makes medicines that use RNA interference, a way to quiet specific genes that cause disease. It sells treatments for rare diseases and high cholesterol, and it has moved from losses to profits while sales climbed quickly. At $223.82 a share, the price looks high compared with the company's accounting value and a conservative value estimate, so the market is already expecting a lot of future success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer